1. Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension. Issue 5 (May 2018) Authors: Kapoor, Raju; Ho, Pei-Ran; Campbell, Nolan; Chang, Ih; Deykin, Aaron; Forrestal, Fiona; Lucas, Nisha; Yu, Bei; Arnold, Douglas L; Freedman, Mark S; Goldman, Myla D; Hartung, Hans-Peter; Havrdová, Eva Kubala; Jeffery, Douglas; Miller, Aaron; Sellebjerg, Finn; Cadavid, Diego; Mikol, Dan; Steiner, D... Journal: Lancet neurology Issue: Volume 17:Issue 5(2018) Page Start: 405 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Safety and efficacy of natalizumab in patients with acute ischaemic stroke (ACTION): a randomised, placebo-controlled, double-blind phase 2 trial. Issue 3 (March 2017) Authors: Elkins, Jacob; Veltkamp, Roland; Montaner, Joan; Johnston, S Claiborne; Singhal, Aneesh B; Becker, Kyra; Lansberg, Maarten G; Tang, Weihua; Chang, Ih; Muralidharan, Kumar; Gheuens, Sarah; Mehta, Lahar; Elkind, Mitchell S V Journal: Lancet neurology Issue: Volume 16:Issue 3(2017:Mar.) Page Start: 217 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial. Issue 9 (September 2019) Authors: Cadavid, Diego; Mellion, Michelle; Hupperts, Raymond; Edwards, Keith R; Calabresi, Peter A; Drulović, Jelena; Giovannoni, Gavin; Hartung, Hans-Peter; Arnold, Douglas L; Fisher, Elizabeth; Rudick, Richard; Mi, Sha; Chai, Yi; Li, Jie; Zhang, Yiwei; Cheng, Wenting; Xu, Lei; Zhu, Bing; Green, Susan M... Journal: Lancet neurology Issue: Volume 18:Issue 9(2019) Page Start: 845 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP). Issue 6 (31st March 2020) Authors: Butzkueven, Helmut; Kappos, Ludwig; Wiendl, Heinz; Trojano, Maria; Spelman, Tim; Chang, Ih; Kasliwal, Rachna; Jaitly, Seema; Campbell, Nolan; Ho, Pei-Ran; Licata, Stephanie Other Names: author non-byline.; Abraham Roby author non-byline.; Adamkova Jana author non-byline.; Airas Laura author non-byline.; Aktas Orhan author non-byline.; Albrecht Holger author non-byline.; Alsassa Roger author non-byline.; de Arcaya Esquide Amaya Alvarez author non-byline.; Angstwurm Klemens autho... Journal: Journal of neurology, neurosurgery and psychiatry Issue: Volume 91:Issue 6(2020) Page Start: 660 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. 071 Natalizumab extended interval dosing (EID) is associated with a significant reduction in progressive multifocal leukoencephalopathy (PML) risk compared with standard interval dosing (SID) in the touch® prescribing program. Issue 6 (24th May 2018) Authors: Ryerson, Lana Zhovtis; Foley, John; Chang, Ih; Kister, Ilya; Cutter, Gary; Metzger, Ryan; Goldberg, Judith D; Li, Xiaochun; Riddle, Evan; Smirnakis, Karen; Yu, Bei; Ren, Zheng; Hotermans, Christophe; Ho, Pei-Ran; Campbell, Nolan Journal: Journal of neurology, neurosurgery and psychiatry Issue: Volume 89:Issue 6(2018) Page Start: A29 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Modeling the Efficacy of Natalizumab in Multiple Sclerosis Patients Who Switch From Every‐4‐Week Dosing to Extended‐Interval Dosing. (19th September 2020) Authors: Chang, Ih; Muralidharan, Kumar Kandadi; Campbell, Nolan; Ho, Pei‐Ran Journal: Journal of clinical pharmacology Issue: Volume 61:Number 3(2021) Page Start: 339 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. 021 Determinants of natalizumab-associated PML outcomes. Issue 6 (27th May 2022) Authors: Kappos, Ludwig; McGuigan, Chris; Derfuss, Tobias; Giovannoni, Gavin; Oh, Jiwon; Ren, Zheng; McCarthy, Kerry; Chang, Ih; Campbell, Nolan Journal: Journal of neurology, neurosurgery and psychiatry Issue: Volume 93:Issue 6(2022) Page Start: A20 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Emraclidine, a novel positive allosteric modulator of cholinergic M4 receptors, for the treatment of schizophrenia: a two-part, randomised, double-blind, placebo-controlled, phase 1b trial. Issue 10369 (17th December 2022) Authors: Krystal, John H; Kane, John M; Correll, Christoph U; Walling, David P; Leoni, Matthew; Duvvuri, Sridhar; Patel, Shrinal; Chang, Ih; Iredale, Philip; Frohlich, Lillian; Versavel, Stacey; Perry, Pamela; Sanchez, Raymond; Renger, John Journal: Lancet Issue: Volume 400:Issue 10369(2022) Page Start: 2210 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. 199 Changes in natalizumab exposure and PML incidence over time. Issue 12 (14th November 2019) Authors: Giovannoni, Gavin; Kappos, Ludwig; Berger, Joseph; Cutter, Gary; Fox, Robert; Wiendl, Heinz; Chang, Ih; Kasliwal, Rachna; Lee, Lily Journal: Journal of neurology, neurosurgery and psychiatry Issue: Volume 90:Issue 12(2019) Page Start: e50 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. The Effect of Hepatic Impairment on the Pharmacokinetics of Asunaprevir, an HCV NS3 Protease Inhibitor. Issue 1 (January 2015) Authors: Eley, Timothy; He, Bing; Chang, Ih; Colston, Elizabeth; Child, Michael; Bedford, William; Kandoussi, Hamza; Pasquinelli, Claudio; Marbury, Thomas C; Bertz, Richard J Journal: Antiviral therapy Issue: Volume 20:Issue 1(2015) Page Start: 29 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗